Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $2.17, $0.58 better than the analyst estimate of $1.59. Revenue for the quarter came in at $794.9 million versus the consensus estimate of $748.62 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.